Login to Your Account


Biocardia pumped: FDA clears the way for phase III heart failure experiment

By Randy Osborne
Staff Writer

Wednesday, November 12, 2014
Biocardia Inc. said the FDA has given its nod to start a phase III trial with CardiAMP, the firm's bone marrow-derived therapy for heart failure, but "we haven't made a decision as to whether or not we will begin the trial without having the full funding in place" to finish, said CEO Peter Altman, and the San Carlos, Calif.-based firm doesn't have enough for that now.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription